Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB03-154 add-on therapy in focal epilepsy
CTR20254561Phase 2Active
- Sponsor
- Zhimeng Biopharma
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CB03-154 in Focal Onset Epilepsy, sponsored by Zhimeng Biopharma. Started Oct 2025; status: active.
02
Drugs
CB03-154
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on CTR20254561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254561.